Genentech, Roche, Tecentriq, Tecentriq Hybreza, atezolizumab, FDA approval, stage III colon cancer, dMMR, ATOMIC study, adjuvant immunotherapy, Phase III trial, oncology

SOUTH SAN FRANCISCO, Calif. — October 8, 2026 Genentech, a member of the Roche Group, announced that the U.S....